Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study

Clinical Cancer Research

Volumn 23, Issue 14, 2017, Pages 3638-3648

  Ramanathan, Ramesh K ^a,b,i   Korn, Ronald L ^a,c   Raghunand, Natarajan ^d   Sachdev, Jasgit C ^a   Newbold, Ronald G ^a,c   Jameson, Gayle ^a   Fetterly, Gerald J ^e,g   Prey, Joshua ^e   Klinz, Stephan G ^f   Kim, Jaeyeon ^f   Cain, Jason ^f   Hendriks, Bart S ^f   Drummond, Daryl C ^f   Bayever, Eliel ^f,h   Fitzgerald, Jonathan B ^f  

^a Virginia G Piper Cancer Center   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c Imaging Endpoints Core Lab   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f MERRIMACK PHARMACEUTICALS   (United States)

^g Athenex Inc   (United States)

^h Glenmark Pharmaceuticals   (United States)

ⁱ MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FERUMOXYTOL; IRINOTECAN SUCROSOFATE; IRON NANOPARTICLE; CAMPTOTHECIN; IRINOTECAN; LIPOSOME; MAGNETITE; NANOPARTICLE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PERMEABILITY; PHANTOM; PILOT STUDY; PRIORITY JOURNAL; SOLID MALIGNANT NEOPLASM; TISSUE SECTION; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOPLASM; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; FEMALE; FERROSOFERRIC OXIDE; HUMANS; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NANOPARTICLES; NEOPLASMS; PILOT PROJECTS;

EID: 85020009712     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1990     Document Type: Article

References (50)

1. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
2. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharma-cokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008;97:4696-740
3. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.
4. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2013;66:2-25.
5. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7:243-54.
6. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998;95:4607-12.
7. Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized nanomedicine. Clin Cancer Res 2012;18:4889-94.
8. Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol 2015;88:20150207.
9. Shields AF, Siegel BA, Miller KD, Munster PN, Ma C, Lee H, et al. Quantification of 64Cu-MM-302 liposome biodistribution and lesion deposition kinetics using PET/CT imaging in advanced breast cancer patients. WMIC 2014;19-SS 109.
10. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006;66:3271-7.
11. Onivyde [package insert]. Cambridge, MA: Merrimack Pharmaceuticals, Inc; 2015.
12. Wang-Gillam A, Li C, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545-57.
13. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
14. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245-59.
15. Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor pro-drug conversion. Cancer Res 2014;74:7003-13.
16. Hendriks BS, Reynolds JG, Klinz SG, Geretti E, Lee H, Leonard SC, et al. Multiscale kinetic modeling of liposomal doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors. CPT Pharmacometrics Syst Pharmacol 2012;1:e15.
17. Karathanasis E, Chan L, Karumbaiah L, McNeeley K, D'Orsi CJ, Annapragada AV, et al. Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers. PLoS One 2009;4: e5843.
18. Daldrup-Link HE, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, et al. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol 1998; 28:67-78.
19. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, et al. Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004;20:138-44.
20. Jensen GM, Bunch TH. Conventional liposome performance and evaluation: lessons from the development of Vescan. J Liposome Res 2007; 17:121-37.
21. 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. Nanomedicine 2015;11:155-65.
22. Izaguirre EW, Sun M, Drummond DC, Kirpotin DB, Funk T, Thompson S, et al. SPECT-CT study of directed drug delivery using In-111 labeled liposomes in a murine mammary carcinoma model. IEEE Nuclear Science Symposium Conference Record 2005;4:1965-8.
23. Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelman RD, Jacobs PM, et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 2009; 75:465-74.
24. Hamilton BE, Nesbit GM, Dosa E, Gahramanov S, Rooney B, Nesbit EG, et al. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 2011;197:981-8.
25. Kalra A, Spernyak J, Kim J, Kamoun W, Sengooba A, Klinz SG, et al. Magnetic resonance imaging with an iron oxide nanoparticle demonstrates preclinically the feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI). Cancer Res 2014;74(19 suppl):2065.
26. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732-40.
27. Miller MA, Gadde S, Pfirschke C, Engblom C, Sprachman MM, Kohler RH, et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci Transl Med 2015;7: 314ra183.
28. Pohlmann A, Karczewski P, Ku M-C, Dieringer B, Waiczies H, Wisbrun N, et al. Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of a1-adrenergic receptor antibodies. NMR Biomed 2014;27:1085-93.
29. Feraheme (ferumoxytol injection) [package insert]. Waltham, MA: AMAG Pharmaceuticals, Inc.; 2009-2015.
30. Daldrup-Link HE, Golovko D, Ruffel B, Denardo DG, Castaneda R, Ansari C, et al. MRI of Tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 2011;17: 5695-704.
31. Merrimack Pharmaceuticals. Pilot study to determine biodistribution of MM-398 and feasibility of ferumoxytol as a tumor imaging agent. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000[cited 2016 Nov 01]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01770353.
32. Mitchell MD, Kundel HL, Axel L, Joseph PM. Agarose as a tissue equivalent phantom material for NMR imaging. Magn Reson Imaging 1986;4:263-6.
33. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 2014;124:1525-36.
34. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogen-esis: applications and potential for drug development. J Natl Cancer Inst 2005;97:172-87.
35. Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013;24: 1567-73.
36. Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005;25:400-10.
37. Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin Pharmacol Ther 2010;88:237-42.
38. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8: 2861-71.
39. Caracciolo G, Farokhzad OC, Mahmoudi M. Biological identity of nanoparticles in vivo: clinical implications of the protein corona. Trends Biotechnol. 2016 Sep 20. [Epub ahead of print]
40. Kalra AV, Kim J, Klinz SG, Paz N, Reutt J, Patel J, et al. The tumor microenvironment modulates the delivery and activation of liposomal encapsulated irinotecan, MM-398. Cancer Res 2013;73(8 suppl):5622.
41. Silverman L, Barenholz Y. In vitro experiments showing enhanced release of doxorubicin from Doxil in the presence of ammonia may explain drug release at tumor site. Nanomedicine 2015;11:1841-50.
42. Klinz S, Zheng J, De Souza R, Ventura M, Paz N, Hedley D, et al. Nanoliposomal irinotecan (nal-IRI) is an active treatment and reduces hypoxia as measured through longitudinal imaging using [18F] FAZA-PET in an orthotopic patient-derived tumorgraft model of pancreatic cancer. Poster #B47, presented at: Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL.
43. Miller MA, Zheng Y-R, Gadde S, Pfirschke C, Zope H, Engblom C, et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun 2015;6: 8692.
44. Storey P, Lim RP, Chandarana H, Rosenkrantz AB, Kim D, Stoffel DR, et al. MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest Radiol 2012;47:717-24.
45. Hernando D, Levin YS, Sirlin CB, Reeder SB. Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging 2014;29:997-1003.
46. Hedgire SS, Mino-Kenudson M, Elmi A, Thayer S, Fernandez-Del Castillo C, Harisinghani MG. Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. Int J Nanomedicine 2014;9:1891-6.
47. Briley-Saebo KC, Johansson LO, Hustvedt SO, Haldorsen AG, Bjørnerud A, Fayad ZA, et al. Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism. Invest Radiol 2006;41:560-71.
48. Kuhlpeter R, Dahnke H, Matuszewski L, Persigehl T, von Wallbrunn A, Allkemper T, et al. R2 and R2 mapping for sensing cell-bound superparamagnetic nanoparticles: in vitro and murine in vivo testing. Radiology 2007;245:449-57.
49. Girard OM, Ramirez R, McCarty S, Mattrey RF. Toward absolute quantification of iron oxide nanoparticles as well as cell internalized fraction using multiparametric MRI. Contrast Media Mol Imaging 2012;7:411-7.
50. Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol 2015;75:579-86.